SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Masaaki Kawano, Katsuma Morikawa, Tatsuya Suda, Naohito Ohno, Sho Matsushita, Toshitaka Akatsuka, Hiroshi Handa, Masanori Matsui, Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants, Virology, 2014, 448, 159

    CrossRef

  2. 2
    Masaaki Kawano, Masanori Matsui, Hiroshi Handa, SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier, Expert Review of Vaccines, 2013, 12, 2, 199

    CrossRef

  3. 3
    Osama E. Rahma, Ed Ashtar, Malgorzata Czystowska, Marta E. Szajnik, Eva Wieckowski, Sarah Bernstein, Vincent E. Herrin, Mortada A. Shams, Seth M. Steinberg, Maria Merino, William Gooding, Carmen Visus, Albert B. DeLeo, Judith K. Wolf, Jeffrey G. Bell, Jay A. Berzofsky, Theresa L. Whiteside, Samir N. Khleif, A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients, Cancer Immunology, Immunotherapy, 2012, 61, 3, 373

    CrossRef

  4. 4
    S J Win, D G G McMillan, F Errington-Mais, V K Ward, S L Young, M A Baird, A A Melcher, Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles, British Journal of Cancer, 2012, 106, 1, 92

    CrossRef

  5. 5
    Tomohiro Kozako, Katsuhiko Fukada, Shinya Hirata, Yohann White, Michiko Harao, Yasuharu Nishimura, Youichiro Kino, Shinji Soeda, Hiroshi Shimeno, François Lemonnier, Shunro Sonoda, Naomichi Arima, Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia, Molecular Immunology, 2009, 47, 2-3, 606

    CrossRef

  6. 6
    Silvia Franceschi, Jack Cuzick, Rolando Herrero, Joakim Dillner, Cosette M. Wheeler, EUROGIN 2008 roadmap on cervical cancer prevention, International Journal of Cancer, 2009, 125, 10
  7. 7
    Anita Satyaprakash, Rosella Creed, Parisa Ravanfar, Natalia Mendoza, Human papillomavirus vaccines, Dermatologic Therapy, 2009, 22, 2
  8. 8
    Anna-Barbara Moscicki, HPV Vaccines: Today and in the Future, Journal of Adolescent Health, 2008, 43, 4, S26

    CrossRef

  9. 9
    Shreya Kanodia, Diane M. Da Silva, W. Martin Kast, Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions, International Journal of Cancer, 2008, 122, 2
  10. 10
    Warner K. Huh, Richard B.S. Roden, The future of vaccines for cervical cancer, Gynecologic Oncology, 2008, 109, 2, S48

    CrossRef

  11. 11
    Sven-Eric Olsson, Luisa L. Villa, Ronaldo L.R. Costa, Carlos A. Petta, Rosires P. Andrade, Christian Malm, Ole-Erik Iversen, John Høye, Margareta Steinwall, Grete Riis-Johannessen, Agneta Andersson-Ellstrom, Kristina Elfgren, Geo von Krogh, Matti Lehtinen, Jorma Paavonen, Gretchen M. Tamms, Katherine Giacoletti, Lisa Lupinacci, Mark T. Esser, Scott C. Vuocolo, Alfred J. Saah, Eliav Barr, Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine, Vaccine, 2007, 25, 26, 4931

    CrossRef

  12. 12
    J.-L. Brun, D. Riethmuller, Vaccination prophylactique et thérapeutique contre le papillomavirus humain, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 2007, 36, 7, 631

    CrossRef

  13. 13
    Alejandro García Carrancá, Silvia C Galván, Vaccines against human papillomavirus: perspectives for controlling cervical cancer, Expert Review of Vaccines, 2007, 6, 4, 497

    CrossRef

  14. 14
    Katie L Green, Kevin Gaston, Development of a Topical Protein Therapeutic for Human Papillomavirus and Associated Cancers, BioDrugs, 2006, 20, 4, 209

    CrossRef